TORONTO, June 12, 2014 /CNW/ - Concordia Healthcare Corp. (TSX: CXR) (OTCQX: CHEHF), today announced that Mark Thompson, Chief
Executive Officer, will present at the 2014 Bloom Burton & Co.
Healthcare Investor Conference in Toronto, Ontario. Concordia's
presentation will take place on Wednesday, June 18, 2014, at 11:00 a.m.
Bloom Burton's third annual healthcare investor conference
features Canada's premier publicly-traded and venture-backed private
companies. The event will attract Canadian, U.S. and European investors
who are interested in the latest developments in Canadian healthcare
Concordia is a diverse healthcare company focused on legacy
pharmaceutical products, orphan drugs, and medical devices for the
diabetic population. The Company's legacy pharmaceutical business
consists of Donnatal®, an adjunctive therapy in the treatment of IBS and acute enterocolitis,
an ADHD-treatment drug, Kapvay® (clonidine extended release tablets), Ulesfia® (benzyl alcohol) Lotion a Head Lice Treatment, and an Asthma-related
medication, Orapred ODT® (prednisolone sodium phosphate orally disintegrating tablets).
Concordia's Specialty Healthcare Distribution (SHD) division (Complete
Medical Homecare) distributes medical supplies targeting diabetes and
related conditions. Concordia's orphan division, Pinnacle, markets
Photofrin® in the United States.
Concordia operates out of facilities in Oakville, Ontario, Bridgetown,
Barbados, Lenexa, Kansas (near Kansas City, Missouri), Bannockburn
(near Chicago), Illinois, and Charlottesville, Virginia.
SOURCE: Concordia Healthcare Corp.
For further information:
Please visit www.concordiarx.com or contact:
Kristen van Vogt
416-815-0700 x 244
416-815-0700 x 225